Seegene Inc. Seegene is the world's leading developer of multiplex molecular technologies and multiplex clinical molecular diagnostics (M-MoDx). Seegene's core enabling technologies -- ACP™, DPO™, READ, and TOCE™ -- are the foundation for multiplex molecular diagnostics and companion diagnostic tests that can simultaneously detect, differentiate, detect minority species and quantitate multiple targets with high sensitivity, specificity and reproducibility. Seegene’s products can be used to diagnose a wide range of disease, including respiratory infections, STDs, TB, HPV, meningitis, diarrhea, H1N1, and many drug resistant pathogens. Seegene also provides personalized genetic tests for diagnosing thyroid cancer, and leukemia, among others. Seegene's products detect multi-pathogens with great reliability and throughput, providing the most economical basis for saving time, labor and cost. Seegene's mission is to maintain leadership in molecular diagnostics for infectious diseases, genetics, pharmacogenetics, and oncology using innovative proprietary technologies. Seegene was founded in Seoul, Korea in 2000, and has subsidiaries in Gaithersburg, MD, U.S.A. and in Eschborn, Germany.